Abstract 14730: Oral Semaglutide Provides Less Value for Money Than Subcutaneous Semaglutide for the Prevention of Major Adverse Cardiovascular Events, but Significantly More Value for Money for the Prevention of Cardiovascular Mortality - KIVIRID

Abstract 14730: Oral Semaglutide Provides Less Value for Money Than Subcutaneous Semaglutide for the Prevention of Major Adverse Cardiovascular Events, but Significantly More Value for Money for the Prevention of Cardiovascular Mortality

Authors: Ronen Arbel, Enis Aboalhasan, Ariel Hammerman, Joseph Azuri

Published: 2021-05-10

DOI: 10.1161/circ.142.suppl_3.14730

Source: Full article

Abstract

Introduction: